Cargando…

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crespi, Gabriela A. N., Hermans, Stefan J., Parker, Michael W., Miles, Luke A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549621/ https://www.ncbi.nlm.nih.gov/pubmed/25880481 http://dx.doi.org/10.1038/srep09649

Ejemplares similares

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013)

ERRATUM: Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
por: Miles, Luke A., et al.
Publicado: (2013)

Copper binding to the Alzheimer’s disease amyloid precursor protein
por: Kong, Geoffrey K.-W., et al.
Publicado: (2007)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Ex vivo(18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
por: Portelius, Erik, et al.
Publicado: (2017)

Small Molecule Binding to Alzheimer Risk Factor CD33 Promotes Aβ Phagocytosis
por: Miles, Luke A., et al.
Publicado: (2019)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Toward the Noninvasive Diagnosis of Alzheimer’s Disease: Molecular Basis for the Specificity of Curcumin for Fibrillar Amyloid-β
por: Khurshid, Beenish, et al.
Publicado: (2022)

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease
por: Ferreira, Sergio T., et al.
Publicado: (2015)

Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
por: Weller, Roy O, et al.
Publicado: (2009)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease
por: Zampar, S., et al.
Publicado: (2020)

Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2015)

β-Amyloid Degradation and Alzheimer's Disease
por: Wang, Deng-Shun, et al.
Publicado: (2006)

Mitochondria, Amyloid β, and Alzheimer's Disease
por: Readnower, Ryan D., et al.
Publicado: (2011)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

A review of β-amyloid neuroimaging in Alzheimer's disease
por: Adlard, Paul A., et al.
Publicado: (2014)

Efficacy and safety of anti‐amyloid‐β immunotherapy for Alzheimer's disease: a systematic review and network meta‐analysis
por: Mo, Jia‐Jie, et al.
Publicado: (2017)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

Molecular modeling of apoE in complexes with Alzheimer’s amyloid-β fibrils from human brain suggests a structural basis for apolipoprotein co-deposition with amyloids
por: Lewkowicz, Emily, et al.
Publicado: (2023)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

A self-destructive nanosweeper that captures and clears amyloid β-peptides
por: Luo, Qiang, et al.
Publicado: (2018)

Polymorphic Structures of Alzheimer's β-Amyloid Globulomers
por: Yu, Xiang, et al.
Publicado: (2011)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Magnetoelectric dissociation of Alzheimer’s β-amyloid aggregates
por: Jang, Jinhyeong, et al.
Publicado: (2022)

Alzheimer’s disease amyloid-β pathology in the lens of the eye
por: Moncaster, Juliet A., et al.
Publicado: (2022)

Amyloid-β (Aβ) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer’s disease mice
por: Taylor, Xavier, et al.
Publicado: (2023)

Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
por: Yadollahikhales, Golnaz, et al.
Publicado: (2023)

Heterogeneous Association of Alzheimer’s Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses
por: Willén, Katarina, et al.
Publicado: (2017)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
por: Roher, Alex E., et al.
Publicado: (2013)

A central role for dityrosine crosslinking of Amyloid-β in Alzheimer’s disease
por: Al-Hilaly, Youssra K, et al.
Publicado: (2013)

Regional differences in Alzheimer’s disease pathology confound behavioural rescue after amyloid-β attenuation
por: Morrone, Christopher D, et al.
Publicado: (2020)

Amyloid β Modification: A Key to the Sporadic Alzheimer's Disease?
por: Barykin, Evgeny P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bm08q44ns1d5irv79tj9s9mio4